P yoderma gangrenosum (PG) is a difficult-to-treat inflammatory skin condition that affects inflammatory bowel disease (IBD) patients. There is no standardized approach for PG treatment. 1 We report the results of 3 patients with Crohn's disease (CD) and refractory PG who had failed several therapies with biologics and were started on tofacitinib for severe inflammatory arthritis with resolution of their PG.
Methods
Patients were treated at the University of North Carolina-Chapel Hill between 2017 and 2018. Immunohistochemical (IHC) staining for phosphorylated Janus kinase (JAK)-1, JAK-2, JAK-3, signal transducer and activator of transcription (STAT)1, and STAT3 was performed on skin biopsy specimens from patients with known PG. Tissue samples were retrieved from a local tissue repository of the Department of Dermatology at the University Hospital Zurich. Antibodies for IHC staining were purchased from Abcam (Cambridge, UK) and Cell Signaling Technology (Danvers, MA). IHC staining of paraffin-embedded tissue slides was performed using the horseradish peroxidase method with diaminobenzidine. 2 The study was approved by the Ethics Committee of the University of North Carolina (18-0375).
Results
The first patient was a 49-year-old woman with CD status post colectomy with ileostomy and new-onset, lower-extremity PG that was refractory to therapy with golimumab, cyclosporine, and ustekinumab. Because of concomitant arthritis with joint effusions, tofacitinib 5 mg twice daily was initiated. Two weeks after starting tofacitinib, PG lesions improved and joint effusions subsided. By 12 weeks, all PG lesions had completely healed.
The second patient was a 24-year-old man with endileostomy after a pouchectomy owing to stricturing and fistulizing CD of the pouch. He developed peristomal PG while on vedolizumab for luminal CD. The PG was not responsive to topical or intralesional steroids. Because of severe arthralgias in small and large joints, he was started on tofacitinib 5 mg twice daily while continuing vedolizumab; the arthralgias and peristomal pyoderma completely healed after 12 weeks ( Figure 1A and B) .
The third patient was a 34-year-old man with a 17-year history of lower-extremity PG with proctectomy and colostomy for perianal CD and previous failure of 2 anti-tumor necrosis factor therapies. He developed worsening PG on his lower extremities despite wellcontrolled luminal disease. Ustekinumab was initiated, but the PG lesions worsened and he developed worsening arthritis with a knee effusion despite recurrent steroid tapers. Ustekinumab was discontinued and tofacitinib 5 mg twice daily was initiated. Within a month, knee effusion, arthritis, and PG lesions improved and steroids were discontinued. Because PG was not completely healed, tofacitinib was increased to 10 mg twice daily and the lesions continue to improve without the need for additional steroid therapy ( Figure 1C  and D) .
Based on these clinical observations we aimed to confirm the role of the JAK-STAT pathway activation in the pathogenesis of PG. We performed IHC staining in skin biopsy specimens of 2 patients from a tissue repository. We detected strong staining of phosphorylated JAK-1, phosphorylated JAK-2, phosphorylated JAK-3, phosphorylated STAT1, and phosphorylated STAT3 in the epidermis (Figure 1E-J) . Phosphorylation is indicative for activation of the JAK/STAT molecules.
Discussion
We report successful treatment of PG with tofacitinib in IBD patients. Tofacitinib is an oral JAK-1 and JAK-3 inhibitor that has been approved for the treatment of rheumatoid arthritis and ulcerative colitis and currently is being evaluated for plaque psoriasis and inflammatory arthritis.
3-6 JAK-STAT signaling is initiated when a cytokine attaches to its target cell surface receptor, which leads to phosphorylation of the receptorassociated JAK molecules followed by phosphorylation of STAT molecules, which translocate to the cell nucleus and activate transcription or suppression of target genes. The JAK/STAT pathways regulate signaling for multiple immune-relevant mediators, which makes their involvement in IBD pathogenesis plausible. 7 Inflammatory arthritis was the indication for tofacitinib in all patients and the arthritis symptoms resolved in all patients within the first 2 to 3 weeks of therapy. Interestingly, PG, which previously had been resistant to various biologics, significantly improved (n ¼ 1) or completely healed (n ¼ 2). Recently, successful PG therapy with a selective JAK-2 inhibitor (ruxolitinib) also was described. 8 With IHC staining, we found the molecular basis for the success of 
phosphorylated STAT1, and (I) phosphorylated STAT3, and (J) negative control of Pyoderma gangrenosum patient skin samples (IHC stains were performed on slides of patient specimens derived from a tissue repository).
